---
title: "Severity-stratified cis-eQTL mapping identifies candidate causal genes for critical COVID-19"
id: "medrxiv-9-severity-stratified-longitudinal-cis-eqtl-mapping-enables-high-sensitivity"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-9-severity-stratified-longitudinal-cis-eqtl-mapping-enables-high-sensitivity"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.14.26365529v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Severity-stratified cis-eQTL mapping identifies candidate causal genes for critical COVID-19
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-9-severity-stratified-longitudinal-cis-eqtl-mapping-enables-high-sensitivity
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.14.26365529v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The preprint reports a longitudinal, severity-stratified mapping of **cis-eQTL** to detect candidate causal genes linked to **critical COVID-19**. - Investigators applied time-resolved genetic regulation analysis across illness severity strata to increase sensitivity for gene discovery; the article title indicates a longitudinal design with stratification by clinical severity. - The authors reported identification of candidate causal genes associated with critical illness, though the source document did not list specific gene names or loci in the accessible text. - The report is a medRxiv preprint and has not undergone peer review; authors and a multi-center consortium are named, including the IMPACC Network and multiple academic institutions. - The source did not provide explicit cohort sizes, sampling intervals, tissue types used for expression quantitative trait locus mapping, or statistical thresholds in the accessible excerpt. - Data availability, replication cohorts, and functional follow-up experiments were not described in the supplied text; the preprint may include these but they were not present in the portion provided. - The study team observed an analytical strategy that, according to the title, increased sensitivity for detecting candidate causal genes by combining severity stratification with longitudinal sampling; exact computational pipelines were not reported in the available content. - Key unanswered questions remain: which specific genes were nominated, how effects varied by time or severity, and whether findings were validated in independent cohorts or functionally characterized—all not documented in the excerpt provided.
## Clinical Analysis & Structured Key Points
Severity-stratified, longitudinal cis-eQTL mapping enables high-sensitivity detection of candidate causal genes for critical COVID-19 | medRxiv Skip to main content Severity-stratified, longitudinal cis-eQTL mapping enables high-sensitivity detection of candidate causal genes for critical COVID-19 View ORCID Profile Ernie Chen , Gisela Gabernet , David B. Corry , Farrah Kheradmand , Lindsey R. Baden , Rafick-Pierre Sekaly , Grace A. McComsey , Elias K. Haddad , Charles B. Cairns , Nadine Rouphael , Ana Fernandez-Sesma , Viviana Simon , Jordan P. Metcalf , Nelson I. Agudelo Higuita , Catherine L. Hough , William B. Messer , Mark M. Davis , Kari C. Nadeau , Bali Pulendran , Holden T. Maecker , Monica Kraft , Chris Bime , Elaine F. Reed , Joanna Schaenman , David J. Erle , Carolyn S. Calfee , Mark A. Atkinson , Scott C. Brakenridge , Esther Melamed , Lauren I. R. Ehrlich , Albert C. Shaw , David A. Hafler , Alison D. Augustine , Patrice M. Becker , Bjoern Peters , Al Ozonoff , Joann Diray-Arce , Ofer Levy , Steven E. Bosinger , Walter Eckalbar , IMPACC Network , Ruth R. Montgomery , Ira M. Hall , Steven H. Kleinstein , View ORCID Profile Dylan Duchen doi: https://doi.org/10.64898/2026.10.14.26365529 Ernie Chen 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ernie Chen Gisela Gabernet 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David B. Corry 2 Baylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Farrah Kheradmand 2 Baylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, TX, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lindsey R. Baden 3 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rafick-Pierre Sekaly 4 Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Grace A. McComsey 4 Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elias K. Haddad 5 Drexel University, Tower Health Hospital, Philadelphia, PA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Charles B. Cairns 5 Drexel University, Tower Health Hospital, Philadelphia, PA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nadine Rouphael 6 Emory School of Medicine, Atlanta, GA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ana Fernandez-Sesma 7 Icahn School of Medicine at Mount Sinai, New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Viviana Simon 7 Icahn School of Medicine at Mount Sinai, New York, NY, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jordan P. Metcalf 8 Oklahoma University Health Sciences Center, Oklahoma City, OK, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nelson I. Agudelo Higuita 8 Oklahoma University Health Sciences Center, Oklahoma City, OK, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catherine L. Hough 9 Oregon Health and Science University, Portland, OR, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site William B. Messer 9 Oregon Health and Science University, Portland, OR, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mark M. Davis 10 Stanford University School of Medicine, Palo Alto, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kari C. Nadeau 10 Stanford University School of Medicine, Palo Alto, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bali Pulendran 10 Stanford University School of Medicine, Palo Alto, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Holden T. Maecker 10 Stanford University School of Medicine, Palo Alto, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Monica Kraft 11 University of Arizona, Tucson, AZ, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chris Bime 11 University of Arizona, Tucson, AZ, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elaine F. Reed 12 David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joanna Schaenman 12 David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David J. Erle 13 Department of Medicine, University of California, San Francisco, California. UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carolyn S. Calfee 13 Department of Medicine, University of California, San Francisco, California. UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mark A. Atkinson 14 University of Florida, Gainesville, FL, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Scott C. Brakenridge 14 University of Florida, Gainesville, FL, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Esther Melamed 15 Dell Medical School at the University of Texas at Austin, Austin, TX, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lauren I. R. Ehrlich 15 Dell Medical School at the University of Texas at Austin, Austin, TX, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Albert C. Shaw 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David A. Hafler 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alison D. Augustine 16 National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patrice M. Becker 16 National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bjoern Peters 17 La Jolla Institute for Immunology, La Jolla, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Al Ozonoff 18 Clinical and Data Coordinating Center (CDCC), Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joann Diray-Arce 18 Clinical and Data Coordinating Center (CDCC), Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ofer Levy 19 Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Steven E. Bosinger 6 Emory School of Medicine, Atlanta, GA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Walter Eckalbar 13 Department of Medicine, University of California, San Francisco, California. UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site 20 - Ruth R. Montgomery 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ira M. Hall 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Steven H. Kleinstein 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dylan Duchen 1 Yale School of Medicine, New Haven, CT, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dylan Duchen For correspondence: dylan.duchen{at}yale.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Host genetic variation influences heterogeneity in infectious disease severity. Genome-wide association studies (GWAS) have identified 69 lead single nucleotide polymorphisms (SNPs) associated with critical COVID-19, but most lack known regulatory mechanisms. To date, the genetic cis-regulatory effects of critical COVID-19 GWAS lead SNPs have not been systematically characterized across acute illness and convalescent phases in a COVID-19 specific cohort. Here, performing severity-stratified, longitudinal cis-expression quantitative trait loci (cis-eQTL) mapping and colocalization with critical COVID-19 GWAS signals, we find that host cis-regulatory effects vary across clinical severity and disease phase. We analyzed peripheral blood mononuclear cells from 1,031 patients in the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC), a prospective multicenter study of adults hospitalized with COVID-19, profiled across 10 timepoints spanning acute illness and convalescence. We identified 23 GWAS lead SNPs that colocalized with cis-eQTLs at 26 candidate causal genes, with 16 detectable only when severity stratification and longitudinal sampling were incorporated. A colocalized, protective allele (chr19:4,717,660) at the TMIGD2 locus upregulated TMIGD2 expression exclusively during the acute phase in the prolonged-critical/fatal cohort, with no detectable effect in the rapid-recovery cohort. Our results show that host genetic effects on critical COVID-19 can be context-dependent, with cis-regulatory effects varying across clinical severity and disease phase. Severity-stratified, longitudinal cis-eQTL designs have greater sensitivity to identify candidate causal genes for critical COVID-19 GWAS associations than single-timepoint cross-sectional studies. Competing Interest Statement The Icahn School of Medicine at Mount Sinai has filed patent applications related to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and therapeutics, listing Florian Krammer and Viviana Simon as co-inventors. Mount Sinai has spun out Kantaro to market SARS-CoV-2 serological tests and Castlevax to develop SARS-CoV-2 vaccines, with Florian Krammer as co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, Curevac, Seqirus, GSK, Pfizer, 3rd Rock Ventures, Sanofi, Gritstone, and Avimex. His laboratory collaborates with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics development. Ofer Levy is a named inventor on patents held by Boston Children's Hospital related to vaccine adjuvants and human in vitro platforms that model vaccine action. His laboratory has received research support from GlaxoSmithKline (GSK) and Pfizer, he is a consultant to GSK and Sanofi, and a co-founder and advisor to ARMR Sciences, which develops immunotherapeutics to prevent opioid overdose. Charles Cairns consults for bioMerieux and receives grant funding from the Bill & Melinda Gates Foundation. James A. Overton is a consultant at Knocean Inc. Jessica Lasky-Su is a scientific advisor for Precion Inc. Scott R. Hutton, Greg Michelloti, and Kari Wong are employees of Metabolon Inc. Vicki Seyfer-Margolis is employed by MyOwnMed. Nadine Rouphael reports grants or contracts with Merck, Sanofi, Pfizer, Vaccine Company, and Immorna. She has served on data safety monitoring and advisory boards for Moderna, AZ, Sanofi, Seqirus, Pfizer, EMMES, ICON, BARDA, Imunon, and CyanVac. She has received travel support from Sanofi and Moderna and honoraria from Virology Education and Krog Consulting. Chris Cotsapas is employed by Vesalius Therapeutics. Adeeb Rahman is employed by Immunai Inc. Steven Kleinstein consults for Peraton related to the ImmPort data repository. Nathan Grubaugh consults for Tempus Labs and the National Basketball Association. Akiko Iwasaki consults for 4BIO, Blue Willow Biologics, Revelar Biotherapeutics, RIGImmune, Xanadu Bio, and Paratus Sciences. Monica Kraft receives research funding from NIH, ALA, Sanofi, and AstraZeneca for asthma research. She consults for AstraZeneca, Sanofi, Chiesi, and GSK for severe asthma and is co-founder and CMO of RaeSedo, Inc., developing peptidomimetics for inflammatory lung disease. Esther Melamed receives research funding from Babson Diagnostics, honoraria from the Multiple Sclerosis Association of America, and has served on advisory boards for Genentech, Horizon, Teva, and Viela Bio. Carolyn Calfee receives research funding from NIH, FDA, DOD, Roche-Genentech, and Quantum Leap Healthcare Collaborative and consults for Janssen, Vasomune, Gen1e Life Sciences, NGMBio, and Cellenkos. Wade Schulz has collaborated with the Shenzhen Center for Health Information and the National Center for Cardiovascular Diseases in Beijing, is a technical consultant for Hugo Health, co-founder of Refactor Health, and has received grants from Merck and Regeneron Pharmaceuticals for COVID-19 research. Grace A. McComsey receives research grants from Redhill, Cognivue, Pfizer, and Genentech and consults for Gilead, Merck, and ViiV/GSK. Linda N. Geng receives research funding from Pfizer, Inc., through her institution. Catherine Hough receives research support from NIH and CDC. David Hafler has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech and consults for Bayer Pharmaceuticals, Repertoire Inc., Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Novartis Pharmaceuticals, and Sanofi Genzyme. Clinical Trial NCT04378777 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NIAID staff conferred with the Department of Health and Human Services Office for Human Research Protections (OHRP) regarding potential applicability of the public health surveillance exception [45CFR46.102 (l) (2)] to the IMPACC study protocol. OHRP concurred that the study satisfied criteria for the public health surveillance exception, and the IMPACC study team sent the study protocol and participant information sheet for review and assessment to institutional review boards (IRBs) at participating institutions. Twelve institutions (Brigham and Women's Hospital/Boston Children's Hospital; Drexel University/Tower Health; Emory University; Icahn School of Medicine at Mount Sinai; Oregon Health & Science University; Stanford University; University of California, Los Angeles; University of Florida; University of Oklahoma Health Sciences Center; Baylor College of Medicine; University of Arizona; and Yale University) elected to conduct the study as public health surveillance, while three sites with prior IRB-approved biobanking protocols elected to integrate and conduct IMPACC under their institutional protocols (University of Texas at Austin, IRB 2020-04-0117; University of California San Francisco, IRB 20-30497; Case Western reserve university, IRB STUDY20200573) with informed consent requirements. Participants enrolled under the public health surveillance exclusion were provided information sheets describing the study, samples to be collected, and plans for data de-identification and use. Those that requested not to participate after reviewing the information sheet were not enrolled. Participants did not receive compensation for study participation while hospitalized and subsequently were offered compensation during outpatient follow-up. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data used for this study are available through the ImmPort database (accession SDY1760) upon approval of data access. The IMPACC genotypes are available through dbGaP (accession phs002686.v3.p2). All analysis code is available at: https://bitbucket.org/kleinstein/impacc-public-code/src/master/eqtl_genetics_manuscript/ https://bitbucket.org/kleinstein/impacc-public-code/src/master/eqtl_genetics_manuscript/ Funder Information Declared National Institute of Allergy and Infectious Diseases, https://ror.org/043z4tv69 National Institute on Drug Abuse National Center for Advancing Translational Sciences, https://ror.org/04pw6fb54 United States National Library of Medicine, https://ror.org/0060t0j89 U.S. National Science Foundation Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Severity-stratified, longitudinal cis-eQTL mapping enables high-sensitivity detection of candidate causal genes for critical COVID-19 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your
## Related Clinical Research

- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Incidence of RSV in Adults ≥50 Years in the Upper Midwest After COVID-19: Community Cohort Finding](https://medichelpline.com/clinical-feed/bmj-open-6-incidence-of-respiratory-syncytial-virus-in-adults-50-years-during-and.md)
- [HRSV Pre-F protein with AlOH, AlOH+CpG, or BFA03: comparative protection in BALB/c mice](https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-comparison-of-the-protective-effect-of-human-respiratory-syncytial-virus-pre-f.md)
- [Changes in recorded incidence of asthma, atopic dermatitis, and multiple sclerosis across the COVI](https://medichelpline.com/clinical-feed/plos-one-6-trends-in-the-incidence-of-asthma-atopic-dermatitis-and-multiple-sclerosis.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.